Biomarkers to Detect Endocrine Therapy Resistance

Description

This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tumor cell (CTC) liquid biopsy will be correlated with clinical response to endocrine therapy and progression-free survival in the above cohort of patients.

Conditions

Metastatic Cancer, Breast Cancer, Lobular Breast Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This pilot observational study is being done to identify possible biomarkers of response to endocrine therapy in patients with ER/PR+ metastatic lobular breast cancer (LBC) starting new endocrine therapy. 18F-fluorofuranylnorprogesterone Positron Emission Tomography/Computed Tomography (FFNP-PET/CT) and liquid biopsies will be performed at baseline and after 4 weeks of treatment. Baseline levels and dynamic on-treatment changes in estrogen signaling as measured by FFNP-PET/CT and circulating tumor cell (CTC) liquid biopsy will be correlated with clinical response to endocrine therapy and progression-free survival in the above cohort of patients.

Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive Lobular Breast Cancer

Biomarkers to Detect Endocrine Therapy Resistance

Condition
Metastatic Cancer
Intervention / Treatment

-

Contacts and Locations

Madison

UW Carbone Cancer Center, Madison, Wisconsin, United States, 53792

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Willing to provide informed consent
  • 2. Individuals at least 18 years of age
  • 3. Have biopsy-proven ER/PR-positive (defined as ER ≥1 percent and PR ≥1 percent by IHC) and HER2-negative advanced or metastatic LBC starting new standard of care endocrine therapy
  • 4. Adequate organ function as indicated by standard laboratory tests (CBC, liver function tests or CMP) allowing for systemic breast cancer treatment per treating oncologist
  • 5. Patients with evaluable bone-only disease that is lytic or mixed lytic-sclerotic are eligible
  • 6. Willing to comply with all study procedures and be available for the duration of the study
  • 7. Disease may be measurable by RECIST 1.1 criteria or non-measurable. Lesion size must be at least 1cm. If only bone lesions present, they should be lytic or mixed lytic-sclerotic. If only liver lesions present, patient is not eligible.
  • 1. Patients with active brain metastases
  • 2. Patients with liver-only disease are not eligible due to high background liver activity related to the radiopharmaceutical's hepatobiliary route of elimination
  • 3. Unable to lie flat during or tolerate PET/CT
  • 4. Patients with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FFNP
  • 5. Presence of liver failure as judged by patient's treating physician
  • 6. Individuals who are pregnant, lactating, or planning on becoming pregnant during the study
  • 7. Not suitable for study participation due to other reasons at the discretion of the investigators
  • 8. Patients with progesterone-receptor negative disease defined as PR \<1 percent by IHC

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Wisconsin, Madison,

Marina Sharifi, MD, PHD, PRINCIPAL_INVESTIGATOR, UW Carbone Cancer Center

Study Record Dates

2026-01